Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P25789
UPID:
PSA4_HUMAN
Alternative names:
Macropain subunit C9; Multicatalytic endopeptidase complex subunit C9; Proteasome component C9; Proteasome subunit L
Alternative UPACC:
P25789; D3DW86; Q53XP2; Q567Q5; Q8TBD1
Background:
Proteasome subunit alpha type-4, also known as Macropain subunit C9, plays a pivotal role in the proteolytic degradation of intracellular proteins. Integral to the 20S core proteasome complex, it is crucial for maintaining cellular protein homeostasis by eliminating misfolded or damaged proteins and regulating protein levels required for cellular functions.
Therapeutic significance:
Understanding the role of Proteasome subunit alpha type-4 could open doors to potential therapeutic strategies. Its involvement in protein degradation pathways highlights its potential as a target for developing treatments aimed at diseases characterized by protein aggregation or misfolding.